95P Italian National Policy to Access Molecular Tumor Boards: Opportunity or Restraint for Precision Oncology?

Edoardo Crimini,L. Boscolo Bielo,Antonio Marra,Matteo Repetto, Elena Rocco,Liliana Ascione,Cristina Zanzottera,Alberto Ranghiero,Carmen Belli,Dario Trapani,C. Criscitiello,Angela Espósito,Gabriella Pravettoni,Gaia Piperno,Daniela Alterio,Costantino Jemos, D Malengo,Emanuela Omodeo Salè,Massimo Barberis,Giuseppe Curigliano

ESMO open（2024）

引用 0|浏览4

暂无评分

摘要

Precision oncology aims to improve clinical outcomes personalizing therapies for patients with cancer. Recently, the Italian Ministry of Health (MoH) established a national policy regulating access to free NGS testing and Molecular Tumor Board (MTB) discussion for patients with no effective therapeutical options, PS ECOG 0-2 and life expectancy ≥ 3 months. In this study, we evaluated if the MoH policy is fit-for-purpose to achieve best outcomes for patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要